All < Article List

MSD Korea applies for reimbursing all 13 indications of Keytruda. Will it lead to a new coverage model?
Pharma Kim Yun-mi 2023.08.11 13:59
Why Hanmi cited MSD as reason behind cruising NASH drug development
Pharma Kim Yun-mi 2023.08.09 11:36
Anticancer drugs Braftovi, Jemperli passes reimbursement panel
Policy Kim Yun-mi 2023.08.04 17:52
Roche shifts reimbursing tactic for Enspryng to outrival AZ’s Soliris
Pharma Kim Yun-mi 2023.08.03 14:01
[Reporter’s notebook] What the government misses by not reimbursing Tagrisso
Opinion Kim Yun-mi 2023.08.02 16:41
Emergence of 3rd-generation BTK inhibitors raises availability question in Korea
Pharma Kim Yun-mi 2023.08.02 13:03
AstraZeneca bets on genomic medicine
Pharma Kim Yun-mi 2023.07.31 12:34
‘Empirical treatment’ essential for fungal infection fatal to blood cancer patients
Hospital Kim Yun-mi 2023.07.26 11:32
Bavencio gets coverage as 1st-line maintenance therapy for urothelial cancer
Pharma Kim Yun-mi 2023.07.25 15:11
‘Failed PV patients desperately need reimbursement for Besremi'
Hospital Kim Yun-mi 2023.07.24 11:28
Local treatment shows efficacy in liver cancer patients with rare metastases
Hospital Kim Yun-mi 2023.07.21 17:03
Breast cancer drug Ibrance expands indication to premenopausal patients
Pharma Kim Yun-mi 2023.07.19 16:13
Boehringer Ingelheim releases new SGLT-2 inhibitor Esgliteo
Pharma Kim Yun-mi 2023.07.17 17:11
MSD Korea expands ERP targets by raising consolatory payment
Pharma Kim Yun-mi 2023.07.17 16:48
Sanofi’s cold agglutinin disease treatment Enjaymo lands in Korea
Pharma Kim Yun-mi 2023.07.13 16:00
Exkivity's clinical value noted in treating rare EGFR exon 20 insertion mutation in NSCLC
Hospital Kim Yun-mi 2023.07.13 14:31
Severe asthma treatment Cinqair passes drug review 6 years after approval
Pharma Kim Yun-mi 2023.07.07 15:55
‘Asthma care in Korea reminds me of Canada 8 years ago’
Bio Kim Yun-mi 2023.07.03 11:48
AstraZeneca to release highly concentrated formulation of orphan drug Ultomiris
Pharma Kim Yun-mi 2023.06.30 14:44
Novartis’ Scemblix gets benefit to treat chronic myeloid leukemia 3rd or more times
Pharma Kim Yun-mi 2023.06.30 11:25

상단영역

본문영역

All articles 목록 ( 총 : 145 )

기사목록 보기 형태

MSD Korea applies for reimbursing all 13 indications of Keytruda. Will it lead to a new coverage model?

Why Hanmi cited MSD as reason behind cruising NASH drug development

Anticancer drugs Braftovi, Jemperli passes reimbursement panel

Roche shifts reimbursing tactic for Enspryng to outrival AZ’s Soliris

[Reporter’s notebook] What the government misses by not reimbursing Tagrisso

Emergence of 3rd-generation BTK inhibitors raises availability question in Korea

AstraZeneca bets on genomic medicine

‘Empirical treatment’ essential for fungal infection fatal to blood cancer patients

Bavencio gets coverage as 1st-line maintenance therapy for urothelial cancer

‘Failed PV patients desperately need reimbursement for Besremi'

Local treatment shows efficacy in liver cancer patients with rare metastases

Breast cancer drug Ibrance expands indication to premenopausal patients

Boehringer Ingelheim releases new SGLT-2 inhibitor Esgliteo

MSD Korea expands ERP targets by raising consolatory payment

Sanofi’s cold agglutinin disease treatment Enjaymo lands in Korea

Exkivity's clinical value noted in treating rare EGFR exon 20 insertion mutation in NSCLC

Severe asthma treatment Cinqair passes drug review 6 years after approval

‘Asthma care in Korea reminds me of Canada 8 years ago’

AstraZeneca to release highly concentrated formulation of orphan drug Ultomiris

Novartis’ Scemblix gets benefit to treat chronic myeloid leukemia 3rd or more times